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Background. We recently demonstrated that the measurement of Mycoplasma pneumoniae (Mp)-specific immunoglobulin (Ig)
M antibody-secreting cells (ASCs) improved diagnosis of Mp infection. Here, we aimed to describe Mp ASC kinetics and duration 
in comparison to conventional measures such as pharyngeal Mp deoxyribonucleic acid (DNA) and serum antibodies.
Methods. This is a prospective longitudinal study of 63 community-acquired pneumonia (CAP) patients and 21 healthy controls 
(HCs), 3–18 years of age, from 2016 to 2017. Mycoplasma pneumoniae ASCs measured by enzyme-linked immunospot assay were 
assessed alongside Mp DNA and antibodies during 6-month follow-up.
Results. Mycoplasma pneumoniae ASCs of the isotype IgM were found in 29 (46%), IgG were found in 27 (43%), and IgA were 
found in 27 (43%) CAP patients. Mycoplasma pneumoniae ASCs were detected from 2 days to a maximum of 6 weeks after symptom 
onset, whereas Mp DNA and antibodies persisted until 4 months (P = .03) and 6 months (P < .01). Mycoplasma pneumoniae ASCs 
were undetectable in HCs, in contrast to detection of Mp DNA in 10 (48%) or antibodies in 6 (29%) controls for a prolonged time. 
The Mp ASC response correlated with clinical disease, but it did not differ between patients treated with or without antibiotics 
against Mp.
Conclusions. Mycoplasma pneumoniae-specific ASCs are short-lived and associated with clinical disease, making it an optimal 
resource for determining Mp pneumonia etiology.
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Mycoplasma pneumoniae (Mp) is a common bacterial pathogen 
of community-acquired pneumonia (CAP) in children [1]. 
The “gold standard” for diagnosing Mp infection is a ≥4-fold 
increase in antibody levels [2] but has low sensitivity [3] and 
is not helpful in acute clinical management because it requires 
acute and convalescent sera [4]. Single immunoglobulin (Ig) M 
levels against Mp and Mp-specific polymerase chain reaction 
(PCR) on upper respiratory tract (URT) samples are currently 
used to diagnose Mp CAP [5, 6]. However, these diagnostic tests 
are also positive in asymptomatic carriers, and therefore they 
are unable to differentiate between Mp infection and carriage 
[7]. We recently demonstrated that the measurement of Mp-
specific IgM antibody-secreting cells (ASCs) by enzyme-linked 
immunospot (ELISpot) assay improved diagnosis of Mp infec-
tion: Mp-specific IgM ASCs were detectable in children with 
Mp CAP but not in Mp carriers suffering from CAP caused by 
other pathogens or asymptomatic Mp carriers [8].
Previous work in vaccine studies has established that cir-
culating antigen-specific B-cell responses are more rapid and 
shorter lived than antibody responses [9, 10]. Antigen-specific 
B cells proliferate and differentiate after antigen exposure into 
ASCs and memory B cells [11, 12]. Antibody-secreting cells 
then circulate in the peripheral blood for up to 2 weeks before 
(1) migrating to secondary lymphoid organs or bone marrow 
or (2) undergoing apoptosis [12, 13]. However, data on the 
human B-cell response during infection rather than following 
controlled antigen challenge via vaccination are scarce. In 
a longitudinal follow-up of our recent study [8], we aimed 
to describe the onset, kinetics, duration, and isotype of the 
antigen-specific plasmablast response after Mp infection in 
children in comparison to more conventional measures such 
as Mp deoxyribonucleic acid (DNA) in the URT and serum 
antibody responses. We further evaluated the effect of dif-
ferent treatment regimens against Mp on the ASC response 
and these other measures.
METHODS
Ethics Statement
The ethics committee of Zurich, Switzerland, approved the 
protocol for this study (no.  2016-00148). Written informed 
consent was obtained from all parents and from children from 
14 years of age.
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Participants
We consecutively enrolled patients between May 1, 2016 and 
April 30, 2017, at University Children’s Hospital Zurich. In all 
children, pharyngeal swab specimens were taken. Blood sam-
ples were collected if additional consent was given. All partici-
pants were invited to participate in this longitudinal follow-up 
study with additional visits between enrollment–2 weeks, 2 
weeks–2 months, and/or 2–6 months after presentation.
Community-Acquired Pneumonia Patients
Community-acquired pneumonia was defined as a clinical 
diagnosis of pneumonia in previously healthy children aged 
3–18  years, as detailed elsewhere [8, 14]. Trained physicians 
identified cases at the emergency department and on pediatric 
wards. Community-acquired pneumonia patients <3  years of 
age were excluded to reduce the probability of viral infection, 
because it is highest in this age group [1, 15–17]. Community-
acquired pneumonia patients were managed by treating phys-
icians, who were not aware of the study test results, according to 
current guidelines [5, 6].
Healthy Controls
Healthy controls (HCs) included healthy children undergoing 
elective surgical procedures and siblings of CAP patients. 
Healthy children undergoing elective surgical procedures were 
age-matched and excluded if there was a history of a recent (≤1 
week) respiratory tract infection. Samples were collected at en-
rollment by the attending anesthesiologist before surgery while 
the child was under general anesthesia. We also recruited and 
followed siblings of CAP patients without evidence of recent 
respiratory tract infection.
Study Procedures
Collection of Biological Samples
Swabs were taken from the posterior pharynx using flocked 
nylon fiber tip swabs (Copan Diagnostics, Murrieta, CA). 
Blood samples were collected in anticoagulated lithium heparin 
blood collection tubes, and fresh peripheral blood mononuclear 
cells (PBMCs) were isolated ≤4 hours after sampling to avoid 
poor assay performance due to decreased ASC viability. The 
PBMCs were isolated by density gradient centrifugation with 
Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden), and via-
bility was assessed by trypan blue exclusion. Serum was stored 
at –80°C.
Mycoplasma pneumoniae Real-Time Polymerase Chain Reaction
Deoxyribonucleic acid isolation was performed on pharyn-
geal swab samples with the QIAamp DNA Mini Kit (QIAGEN, 
Hilden, Germany). A quantitative TaqMan (Applied Biosystems, 
Foster City, CA) real-time PCR assay was used to detect and 
quantify Mp DNA as described previously [18].
Mycoplasma pneumoniae-Specific Enzyme-Linked 
Immunosorbent Assay
Mycoplasma pneumoniae-specific IgM, IgG, and IgA antibody 
levels were determined using a commercially available enzyme-
linked immunosorbent assay (Virion\Serion, Würzburg, 
Germany), according to the manufacturer’s instructions.
Mycoplasma pneumoniae-Specific Antibody-Secreting Cell Enzyme-
Linked Immunospot Assay
The frequency of circulating Mp-specific IgM, IgG, and IgA 
ASCs was measured by ELISpot assay using fresh PBMCs, as 
described previously [19], with some modifications. In brief, 
96-well ELISpot filter plates (Millipore, Billerica, MA) were 
coated for 90 minutes at 37°C with the different antigens di-
luted in sterile phosphate-buffered saline (PBS). The antigens 
were as follows: detergent extract of Mp enriched for highly 
specific adhesion protein P1 (2  µg/mL; Virion\Serion); 
Fluarix Tetra quadrivalent influenza A  and B virus vaccine 
(6  µg/mL; GlaxoSmithKline, Middlesex, UK); and affinity-
purified antibodies to human Ig light chains (λ and κ, 10 µg/
mL; SouthernBiotech, Birmingham, AL) as the positive con-
trol. The negative control consisted of PBS only in uncoated 
wells. After washing, coated plates were blocked with me-
dium for another 90 minutes at 37°C. Coated plates were in-
cubated at 37°C for 16–20 hours with 100 000 or 10 000 viable 
PBMCs, and each dilution was used in triplicate. Plates were 
then washed, incubated with biotinylated anti-IgM, -IgG, -IgA 
and alkaline phosphatase (AP)-conjugated streptavidin (all 
SouthernBiotech), and spots visualized using an AP substrate 
kit (Bio-Rad Laboratories, Hercules, CA), with each spot ap-
pearing at the former location of a single ASC. Spots were 
counted by an ELISpot reader (AID, Strassberg, Germany) 
using predefined settings. The spots identified by the ma-
chine were manually inspected for the presence of artifacts. 
Antigen-specific spot counts were calculated as the mean of 
3 wells minus the mean number of spots in PBS wells. Data 
were expressed as ASCs per 106 viable PBMCs [19].
Statistical Analysis
We report dichotomous variables as percentages and contin-
uous variables as medians with interquartile ranges (IQRs). 
The Mann-Whitney U test was used to compare medians, 
and the Fisher exact test was used to compare proportions. 
Spearman rank correlation was used to evaluate relation-
ships between variables. Kinetics were plotted with smooth 
curves, fitted by loess (with a span of 0.67) using the scatter.
smooth formula [20]. Study design and sample size consid-
erations were described in detail previously [8]. All reported 
P values are 2-tailed with statistical significance defined as P 
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RESULTS
Study Population
During the 12-month study period, we screened 450 CAP pa-
tients and 156 HCs (Figure 1). A total of 152 CAP patients and 
156 HCs were enrolled (Table  1). Mycoplasma pneumoniae-
specific PCR and serological test results of the enrolled popu-
lation are shown in Table 2. We included 63 CAP patients and 
21 HCs with fresh (isolated ≤4 hours) PBMCs available for 
additional testing with the Mp-specific ASC ELISpot assay, as 
previously reported [8]. There were no statistically significant 
differences between included and overall enrolled CAP pa-
tients and HCs in regards to age, sex, and season at enrollment 
(Table 1). However, the proportion of siblings of index patients 
among HCs was higher in the included group of controls com-
pared with enrolled controls (43% vs 12%, P < .01). Clinical, 
radiological, and laboratory characteristics of included CAP 
patients have been described separately [14, 21].
Kinetics and Duration of the Antibody-Secreting Cell Response
We first assessed the ASC response at presentation and found 
Mp-specific ASCs in CAP patients (n = 63) of the isotype IgM, 
IgG, and IgA in 29 (46%), 27 (43%), and 27 (43%), respectively 
(Table  2). These first samples were collected at a median of 
12 days after onset of symptoms (IQR, 11–16; range, 2–29). Then, 
the median number of Mp IgM ASCs was 690 (IQR, 200–1933) 
spots per 106 PBMCs, which was higher than that of Mp IgG 
ASCs (median 300; IQR, 166–533; P = .07) and Mp IgA ASCs 
(median 167; IQR, 67–333; P < .01). Mycoplasma pneumoniae-
specific  IgM ASCs correlated with Mp IgG ASCs (rho 0.63; 
P < .01) and Mp IgA ASCs (rho 0.62; P < .01) but not with Mp 
antibody (any isotype) or Mp DNA levels (Supplementary Table 
1). Time since onset of symptoms positively correlated with Mp 
IgM and Mp IgG antibody levels (rho 0.56 and 0.53; P < .01), 
but not with Mp ASCs (any isotype), in first measured sample 
(Supplementary Table 2). Among HCs (n = 21), no Mp ASCs 
were detected, but Mp IgM serology was positive in 6 (29%) in-
dividuals, 1 (5%) of whom showed seroconversion to Mp IgG 
with a >4-fold increase in Mp IgG (Table  2). All 29 Mp IgM 
ASC-positive CAP patients were also Mp PCR-positive and Mp 
IgM-positive, and the 3 (5%) Mp PCR-positive patients, who 
were Mp IgM ASC- and Mp IgM-negative, were identified as 
Mp carriers suffering from CAP caused by other pathogens, 
as detailed elsewhere [8]. The specificity of the Mp IgM ASC 
ELISpot assay was further demonstrated by the absence of Mp 
IgM ASCs in influenza virus [14] and Epstein-Barr virus (EBV) 
[22] infected patients (Supplementary Figure 1). The 2 patients 
who tested positive for influenza virus in pharyngeal swab 
samples [14] had influenza-specific but not Mp-specific ASCs 
 detectable during CAP.
The longitudinal follow-up study included 52 (62%) children 
(41 CAP patients and 11 HCs) with >2 visits in 42 (81%) 
and >3 visits in 27 (52%) children, performed at <2 weeks, 2 
weeks–2 months, and 2–6 months in 43 (83%), 38 (73%), and 
38 (73%) individuals, respectively. Mycoplasma pneumoniae 
A B
450 Children screened
152 (34%) Children enrolled
63 (41%) Children included
156 Children screened






298 (66%) not eligible
196 (66%)
102 (34%)




55 (62%) no blood samples
34 (38%) no fresh PBMCs
specimens
135 (87%) incomplete
17 (13%) no blood samples
118 (87%) no fresh PBMCs
specimens
(isolated ≤4 h)(isolated ≤4 h)
21 (13%) Children included
12 (57%) elective surgery
9 (43%) siblings
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ASCs were detected only within 6 weeks after symptom onset 
(Figure  2), in contrast to Mp DNA (P = .03) and Mp IgM 
and Mp IgG (P < .01) persisting at 4 and 6 months, respec-
tively (Supplementary Table 3). The Mp IgA levels in CAP pa-
tients were low (median 11 U/mL, IQR 6–25) and above the 
cutoff in only 13 (21%) (Table  2) and differed significantly 
from Mp IgM (P < .01) and Mp IgG (P < .01) levels. However, 
Mp antibody levels and kinetics correlated between isotypes 
(Supplementary Table 1 and Figure  2). Detecting a ≥4-fold 
Mp IgG increase in Mp IgM ASC-positive patients was sig-
nificantly more likely with Mp IgG <20 U/mL (91%, n = 10 
of 11)  compared with Mp IgG ≥20 U/mL (0%, n = 0 of 18; 
P < .01) at presentation.
It is interesting to note that 3 siblings of CAP patients de-
veloped CAP during follow-up and were then also tested pos-
itive for Mp IgM ASCs. One of the 3 siblings was sampled (as 
asymptomatic sibling of a CAP patient) 3 days before the onset 
of symptoms, and at this time point, the sibling tested nega-
tive by the Mp ASC ELISpot assay, followed by a positive Mp 
ASC ELISpot assay result 6 days after developing symptoms and 
CAP diagnosis. Representative Mp IgM ASC ELISpot assay re-
sponses in this patient are shown in Figure 3. The kinetics of Mp 
DNA, Mp antibodies, and Mp ASCs of this patient are indicated 
in black in Supplementary Figure 2.
In HCs, Mp DNA and/or Mp IgM and IgG were detected 
for up to ≥2  months, whereas Mp ASCs and Mp IgA levels 
were negative during the complete 6-month follow-up period 
(Figure 4). These results were in line with the lack of respiratory 
symptoms during follow-up visits.
Relation of the Antibody-Secreting Cell Response With Clinical Disease
We next compared the ASC response with clinical disease. 
As previously demonstrated in this cohort [14], Mp IgM 
ASC-positive CAP was statistically associated with prolonged 
prodromal symptoms and extrapulmonary manifestations, pre-
dominantly skin disorders [21]. However, the magnitude of the 
Mp-specific ASC response did not correlate with any of these 
clinical features (Supplementary Table 2). Furthermore, lower 
levels of C-reactive protein (CRP), white blood cell (WBC) 
count, absolute neutrophil count (ANC), and procalcitonin 
were statistically associated with IgM ASC-positive Mp in-
fection [14]. Mycoplasma pneumoniae IgM ASC responses 
correlated positively with CRP levels (rho 0.45; P = .01), and 
negatively with WBC count (rho −.61; P < .01) and ANC 
(rho −.66; P < .01), but not with other laboratory parameters 
(Supplementary Table 2).
Next, we evaluated the effect of different treatment regimens 
against Mp on the ASC response. Ten (34.5%) patients received 
Table 1. Baseline Characteristics of CAP Patients and Controlsa
Characteristics 
CAP HC
OR (95% CI) P
Included (n = 63) Enrolled (n = 152) Included (n = 21) Enrolled (n = 156)
n = 12 (57) Elective Surgery
n = 137 (88) Elective 
Surgery
n = 9 (43) Siblings n = 19 (12) Siblings
Age (years), median (IQR) 6.0 (4.4–10.2) 5.7 (4.3–8.9) 6.1 (4.9–7.9) 5.9 (4.3–8.1) – .91
Sex (male), n (%) 39 (62) 84 (55) 17 (81) 102 (65) .4 (.1–1.4) .18
Season at enrollment, n (%)       
 Spring (March–May) 11 (17) 21 (14) 5 (24) 43 (28) .7 (.2–2.9) .53
 Summer (June–August) 13 (21) 30 (20) 9 (43) 22 (14) .4 (.1–1.2) .08
 Autumn (September–November) 17 (27) 37 (24) 4 (19) 17 (11) 1.6 (.4–7.3) .57
 Winter (December–February) 22 (35) 64 (42) 3 (14) 74 (47) 3.2 (.8–18.7) .10
Day-care or preschool attendance, 
n (%)
63 (100) NA 20 (95) NA NA .25
Immunizationsb, n (%) 52/55 (95) NA 14/14 (100) NA NA 1.00
Underlying disease, n (%) 10 (16) 32 (21) 12 (57) 137 (88) .1 (.0–.5) <.01
 ENT, n 0 4 12 137c   
 Asthma or history of wheezing, n 2 8 0 0   
 Cardiovascular, n 0 2 0 0   
 Gastrointestinal, n 2 2 0 0   
 Neurological, n 2 5 0 0   
 Other, n 4 11 0 0   
Abbreviations: CAP, community-acquired pneumonia; CI, confidence interval; ENT, ear, nose, and throat; HC, healthy control; IQR, interquartile range; NA, not available; OR, odds ratio.
aDifferences between included CAP and included HC children (in bold) were determined by the Mann-Whitney U test (medians) and Fisher exact test (proportions). P < .05 are indicated in 
bold.
b“Immunizations” refer to being immunized per the national immunization schedule in Switzerland.
cChildren with elective surgery at the division of otolaryngology (n = 137): hyperplasia of adenoids (n = 62); eustachian catarrh (n = 26); cysts, fistulae, and sinuses (n = 10); protruding ears 
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clarithromycin, 10 (34.5%) patients received doxycycline, and 9 
(31%) patients were not treated with any antibiotic in vitro ac-
tive against Mp (ie, amoxicillin [n = 5], amoxicillin-clavulanate 
[n = 1], ceftriaxone [n = 1], no antibiotic treatment [n = 2]). 
Kinetics of pharyngeal Mp DNA, Mp antibodies, and Mp ASCs 
according to different treatment management are shown in 
Figure 5. There were no statistically significant differences be-
tween patients with or without treatment in vitro active against 
Mp with regards to ASC and antibody responses (Supplementary 
Table 4). In contrast, Mp DNA was detected in patients treated 
with clarithromycin and doxycycline in 58% and 90% at 1- to 
2-month follow-up (P = .01) and 38% and 0% at 3- to 4-month 
follow-up (P = .20), respectively. It is notable that clinical out-
come (length of hospital stay and long-term sequelae) and 
fever duration was not statistically different between treatment 
groups (Supplementary Figure 3). Five patients who received 
antibiotics against Mp were additionally treated with cortico-
steroids because of severe extrapulmonary mucocutaneous 
Table 2. Mp-Specific Test Results of Enrolled and Included CAP Patients and Controlsa
Diagnostic Test CAP HC OR (95% CI) P
Enrolled Cohort (n = 152) (n = 156)   
Mp-specific DNA 44 (29) 12 (8)  
6/137 (4) elective surgery  
6/19 (32) siblings
4.9 (2.4–10.6) <.01
Mp-specific Antibodies     
IgM+ 39/97* (40) 15/139* (11) 5.5 (2.7–11.7) <.01
IgG+ 39/97 (40) 16/139 (12) 5.1 (2.6–10.7) <.01
IgA+ 24/97 (25) 0/139 (0) NA <.01
IgM+ IgG+ 37/97 (38) 7/139 (5) 11.5 (4.7–32.3) <.01
IgM+ IgA+ 24/97 (25) 0/139 (0) NA <.01
IgG+ IgA+ 23/97 (24) 0/139 (0) NA <.01
IgM+ IgG+ IgA+ 23/97 (24) 0/139 (0) NA <.01
Included Cohort (n = 63) (n = 21)   
Mp-specific DNA 32 (51) 10 (48)  
4/12 (33) elective surgery  
6/9 (66) siblings
1.1 (.4–3.5) 1.00
Mp-specific Antibodies     
IgM+ 32 (51) 6 (29) 2.6 (.8–9.1) .08
IgG+ 27 (43) 5 (24) 2.4 (.7–9.4) .19
IgA+ 13 (21) 0 (0) NA .03
IgM+ IgG+ 26 (41) 5 (24) 2.2 (.7–8.8) .20
IgM+ IgA+ 13 (21) 0 (0) NA .03
IgG+ IgA+ 11 (17) 0 (0) NA .06
IgM+ IgG+ IgA+ 11 (17) 0 (0) NA .06
Seroconversion:     
 IgM 0/38** (0) 0/11** (0) – 1.00
 IgG 5/38 (13) 1/11 (9) 1.5 (.1–78.7) 1.00
 IgA 5/38 (13) 0/11 (0) NA .57
Class switch from IgM to IgG 7/38 (18) 1/11 (9) 2.2 (.2–111.7) .66
Titer Increase:     
 IgM ≥2-fold [3] 3/38 (8) 0/11 (0) NA 1.00
 IgG ≥4-fold [2] 10/38 (26) 1/11 (9) 3.5 (.4–170.1) .41
Mp-specific ASC     
IgM ASC+ 29 (46) 0 (0) NA <.01
IgG ASC+ 27 (43) 0 (0) NA <.01
IgA ASC+ 27 (43) 0 (0) NA <.01
IgM ASC+ IgG ASC+ 27 (43) 0 (0) NA <.01
IgM ASC+ IgA ASC+ 27 (43) 0 (0) NA <.01
IgG ASC+ IgA ASC+ 26 (41) 0 (0) NA <.01
IgM ASC+ IgG ASC+ IgA ASC+ 26 (41) 0 (0) NA <.01
Abbreviations: ASC, antibody-secreting cells; CAP, community-acquired pneumonia; CI, confidence interval; DNA, deoxyribonucleic acid; HC, healthy control; Ig, immunoglobulin; Mp, 
Mycoplasma pneumoniae; NA, not available; OR, odds ratio.
aData are presented as no. (%). Differences between groups are indicated by the Fisher exact test. P < .05 are indicated in bold.
*Sera were available in 97 (64%) CAP patients and 139 (89%) controls.
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manifestations [21]. Mycoplasma pneumoniae IgM ASC num-
bers did not differ between those patients before corticosteroid 
treatment and other CAP patients at an early time point (<2 
weeks after onset of symptoms) (P = .49), but they were signifi-
cantly lower at a later time point (2–4 weeks after onset of symp-
toms) after the administration of corticosteroids compared with 

















































0 2 4 6 8 10 12 14 16 18 20 22 24
Time after onset of symptoms (weeks)
0 2 4 6 8 10 12 14 16 18 20 22 24
Time after onset of symptoms (weeks)
0 2 4 6 8 10 12 14 16 18 20 22 24
Time after onset of symptoms (weeks)
0 2 4 6 8 10 12 14 16 18 20 22 24
Time after onset of symptoms (weeks)
















































Time after onset of symptoms (weeks)



























Time after onset of symptoms (weeks)





































Figure 2. Kinetics of pharyngeal Mycoplasma pneumoniae (Mp) deoxyribonucleic acid (DNA) levels, Mp antibodies, and Mp antibody-secreting cells (ASCs) in Mp immu-
noglobulin (Ig) M ASC-positive community-acquired pneumonia patients. (A) Mycoplasma pneumoniae DNA levels in pharyngeal swab samples as genomic copy number per 
milliliter. (B–D) Mycoplasma pneumoniae antibodies and Mp ASCs of the isotype IgM (B), IgG (C), and IgA (D). Smooth curves fitted by loess (with a span of 0.67) and original 
data as dots are shown. The dashed horizontal lines represent the cutoff for the enzyme-linked immunosorbent assay, and lower limits of quantification for IgM, IgG, and IgA 
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CAP patients without corticosteroid treatment sampled at the 
same time period (P = .04) (Supplementary Figure 4).
DISCUSSION
In this longitudinal follow-up study, we demonstrate that Mp-
specific ASCs are short-lived and associated with clinical dis-
ease, in contrast to pharyngeal Mp DNA and serum antibodies 
that can persist for months and may be present also during Mp 
carriage. This study adds to our recent work [8] by detailing 
the onset, kinetics, duration, and isotype (IgM/IgG/IgA) of 
the antigen-specific plasmablast response after Mp infection 
in children and investigating the effect of different treatment 
regimens against Mp on the specific immune response and 
pharyngeal Mp DNA load. These findings expand our current 
knowledge on specific B-cell responses to infection and provide 
an explanation for the high specificity and sensitivity of the Mp 
ASC ELISpot assay during Mp CAP [8]. The data presented give 
insight into disease pathophysiology and can therefore serve as 
a model for developing better diagnostic tests for other child-
hood infectious diseases.
We detected Mp ASCs as early as 2 days after the presenta-
tion of clinical symptoms, which was in line with the only pre-
vious study on Mp-specific ASCs including 12 Mp-seropositive 
children with CAP, in which Mp ASCs were detected within 
5 days after symptom onset [23]. To our knowledge, we assessed 
also for the first time B-cell responses in a patient shortly before 
the development of symptoms and could thereby exemplarily 
demonstrate a specific ASC response upon CAP onset, which 
disappeared again with disease resolution, whereas Mp DNA 
and antibodies persisted for prolonged time. Mycoplasma 
pneumoniae-specific ASCs peaked approximately 1–2 
weeks after onset of symptoms, similar to previous work: we re-
cently reviewed the literature on the ASC response to infection 
[9] and found that the timing of ASC appearance in the blood 
is highly consistent after infection across several pathogens. 
Antibody-secreting cells are first detectable in peripheral blood 
at approximately 4 days after onset of symptoms before peaking 
at days 6–8 [9, 24]. In contrast to the conserved timing of ASC 
appearance, the magnitude of ASC responses varies widely be-
tween different bacterial and viral pathogens as well as between 
ASC isotypes [9]. Our results are consistent with previous work 
studying the immune responses to both vaccination [13] and 
infection [9], and they demonstrate a synchronized response 
of B cells with different isotypes during infection. In contrast, 
serum antibody responses showed a sequential appearance in 
our study: IgM and IgA were first detectable followed by IgG 
with concentrations that were still rising in the first 4 weeks 
after symptom onset and lasting for several months.
However, in some individuals, B-cell responses could be de-
tected up to 6 weeks after onset of symptoms, indicating that 
Mp-specific ASCs may circulate longer compared with other 
(respiratory) infections, in which antigen-specific ASCs dis-
appeared in most cases already 14  days after symptom onset 










Mp Influenza PBS Total IgM
Figure 3. Enzyme-linked immunospot (ELISpot) assay for antibody-secreting cells in a patient who developed Mycoplasma pneumoniae (Mp) community-acquired pneu-
monia. Representative patterns of ELISpot assay wells 3 days before the onset of symptoms (A) and on day 6 (B) and day 81 (C) after symptom onset (100 000 peripheral blood 
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slow disease progression in Mp CAP [14], which may result 
in a longer antigen exposure and therefore immune activa-
tion, which allows detection of Mp-specific ASCs in all patients 
during CAP. A more prolonged antigen exposure with slow dis-
ease progression may also be the reason for the significantly in-
creased Mp IgG levels already in the first serum sample of Mp 
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Figure 4. Kinetics of pharyngeal Mycoplasma pneumoniae (Mp) deoxyribonucleic acid (DNA) levels, Mp antibodies, and Mp antibody-secreting cells (ASCs) in Mp poly-
merase chain reaction (PCR)-positive controls. (A) Mycoplasma pneumoniae DNA levels in pharyngeal swab samples as genomic copy number per milliliter. (B–D) Mycoplasma 
pneumoniae antibodies and Mp ASCs of the isotype immunoglobulin (Ig) M (B), IgG (C), and IgA (D). Smooth curves fitted by loess (with a span of 0.67) and original data as 
dots are shown. The dashed horizontal lines represent the cutoff for the enzyme-linked immunosorbent assay, and lower limits of quantification for IgM, IgG, and IgA are 5, 
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Figure 5. Kinetics of pharyngeal Mycoplasma pneumoniae (Mp) deoxyribonucleic acid levels, Mp antibodies, and Mp antibody-secreting cells (ASCs) in Mp immunoglob-
ulin (Ig) M ASC-positive community-acquired pneumonia patients according to different treatment management. (A) β-lactam antibiotics (n = 7) or no treatment (n = 2). (B) 
Macrolide (clarithromycin) (n = 10). (C) Doxycycline (n = 10). Smooth curves fitted by loess (with a span of 0.67) and original data as dots are shown. The dashed horizontal 
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IgM ASC-positive CAP patients. The development of a further 
increase of Mp IgG in those patients ≥4-fold was therefore very 
unlikely, which continues to question its value as gold standard 
for diagnosing Mp infection [3, 4]. Its interpretation is also 
complicated by our observation of a >4-fold increase in Mp IgG 
level in an asymptomatic sibling.
Besides describing Mp ASC response kinetics and dura-
tion, we also determined antibody specificity and isotype of 
the plasmablast response to infection, which are key to develop 
accurate ASC measurements [9]. We showed that Mp-specific 
ASCs were not detectable in patients infected with influenza 
virus or EBV, whereas patients with influenza virus infection 
on the other hand developed influenza virus-specific ASC re-
sponses during CAP. The detection of Mp IgM ASCs was more 
sensitive than the detection of Mp IgG ASCs or Mp IgA ASCs for 
determining Mp infection, again in line with previous work [23].
The Mp-specific ASC response was associated with clin-
ical disease and correlated with CRP levels and WBC counts. 
Although Mp CAP was associated with lower CRP levels com-
pared with CAP of other origin [14], severe disease defined as 
the presence of extrapulmonary skin manifestations was asso-
ciated with increased systemic inflammation and higher CRP 
levels [21]. This finding suggests that in these children, inflam-
mation may be indeed driven by Mp antigens, which warrants 
further investigation. It is interesting to note that there were no 
differences in ASC or antibody responses, or clinical outcomes 
such as fever duration, between groups with different antibiotic 
treatment regimens. In contrast, corticosteroid treatment sig-
nificantly decreased ASC responses, although they were still de-
tectable. One third of Mp IgM ASC-positive CAP patients were 
not treated with an antibiotic in vitro active against Mp, but all 
of them equally and fully recovered. Although the study design 
does not allow conclusions about the effectiveness of treatment, 
these findings highlight the need for future interventional 
studies to assess the efficacy of antibiotics for Mp CAP [2, 31].
The ASC ELISpot assay is a robust technique [9, 32], and 
the protocol described here could be translated directly into 
the clinical setting to diagnose Mp infection by using only a 
small volume of peripheral blood (≥1 mL). However, the ASC 
ELISpot assay is labor-intensive, requiring the handling of fresh 
or frozen PBMCs [19, 32], and has a rather long overall turna-
round time (~24 hours), but recent alternative protocols suggest 
more rapid (~6–8 hours) ASC detection [19]. Optimizing such 
protocols will help to routinely use the Mp IgM ASC ELISpot 
assay for diagnosing Mp CAP.
Despite variation in sampling time points, the study popula-
tion represents a well defined cohort of children, both patients 
and controls, in whom pharyngeal swabs and fresh blood sam-
ples at several time points up to 6 months after inclusion could 
be obtained. It is challenging to collect blood samples from 
healthy children and already recovered children, and we can 
therefore not fully exclude any selection bias that occurred in 
the included subgroup of study participants. However, baseline 
characteristics of both included CAP patients and controls were 
similar compared with the enrolled study population. Some of 
the siblings of index patients were included as controls, which 
made it possible to increase the likelihood of detecting asymp-
tomatic Mp carriers and to investigate the pattern symptom ac-
quisition and/or changes in the results of the diagnostic tests. 
Mycoplasma pneumoniae was indeed more frequently detected 
in the URT of siblings compared with controls sampled during 
elective surgery (32% vs 4%), which is in line with a higher Mp 
transmission rate within families and between other close con-
tacts [14, 33, 34]. Proportionally, more siblings than other con-
trols were included than were initially enrolled into the study 
(43% vs 12%), which may be partly due to a higher motivation 
of family members of affected patients agreeing to multiple 
sampling and follow-up. This may also explain the differences 
in Mp detection rates between included and enrolled study par-
ticipants. A larger prospective confirmatory study is needed to 
validate these promising results of the Mp ASC ELISpot assay 
and to examine the added clinical utility of the ASC ELISpot 
assay to diagnose Mp infection in the clinical care of children 
with CAP.
CONCLUSIONS
In conclusion, Mp-specific ASCs are short-lived and associated 
with clinical disease, in contrast to pharyngeal Mp DNA and 
serum antibodies. There are limited data on the duration of 
B-cell responses during infection, and our study indicates that 
Mp-specific peripheral blood B cells appear early in the course 
of illness, last only for several weeks before disappearing com-
pletely, and therefore they can be easily detected in a clinical 
setting with good diagnostic sensitivity and specificity. These 
findings expand our current knowledge on specific B-cell re-
sponses to infection, and they reveal ASCs as an optimal re-
source for determining disease etiology in Mp pneumonia and 
possibly other childhood infections.
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